Skip to main content
. 2019 Feb 19;10:99. doi: 10.3389/fphar.2019.00099

FIGURE 3.

FIGURE 3

(A) Time to first weight gain concern during es/citalopram treatment is associated with CYP2C19 metabolizer status (p = 0.018, log-rank test for trend). B, Number of activation side effects during es/citalopram treatment is associated with CYP2C19 metabolizer status (p = 0.029, one-way ANOVA with test for trend). Median and interquartile range are indicated by the bar and whiskers. PM, poor metabolizer; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer; n, number.